Swedish Orphan Biovitrum AB (CHIX:SOBIS) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:SOBIS Swedish Orphan Biovitrum AB CHIX:SOBIS
85 GF Score
Price kr465.60
GF Value kr360.11
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB FFO per Share?

FFO per Share only applies to REITs.

CHIX:SOBIS
85GF Score
Swedish Orphan Biovitrum AB CHIX:SOBIS
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Swedish Orphan Biovitrum AB (CHIX:SOBIS) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of kr465.60 is trading 29.3% above its estimated GF Value™ of kr360.11. GuruFocus considers Swedish Orphan Biovitrum AB to be Modestly Overvalued.

Key valuation signals for CHIX:SOBIS:

  • FFO per Share:
  • GF Value™: kr360.11 vs. price of kr465.60 (29.3% above fair value)
  • GF Score™: 85/100 with 6 warning signs

No single metric tells the full story. See the CHIX:SOBIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
85GF Score

Get the complete analysis for CHIX:SOBIS

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr465.60
Price
kr360.11
GF Value